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Abstract
Introduction In North-West Europe, cardiovascular disease
is still a major cause of death and despite several efforts (e.g.
European guidelines and conferences) cardiovascular risk
factors are still inconsistently diagnosed and treated.
Methods Weevaluated thefirst consultations of patients intwo
cardiovascular referral clinics in France and the Netherlands,
while evaluating the differences in national guidelines and
between the profiles of patients at their first consultation.
Results Notable differences exist between the two locally
used guidelines in their programmes of cardiovascular risk
assessment and their definition of LDL-cholesterol target
levels. With regard to the LDL-cholesterol levels, more
patients are ‘on target’ when using the French guideline than
when using the Dutch guideline. Evaluation of the patient’s
profile at first presentation showed that the LDL-cholesterol
levels were significantly lower in the Dutch patients (n=77)
compared with the French patients (n=119). Dutch patients
used significantly more statins than French patients.
Conclusion Despite the small study population included in
this study, we found that comparison of daily care (as part
of a primary prevention programme) is rather difficult due
to several national differences in the approach to patients.
All these factors combined should be taken into account,
when discussing and extrapolating results obtained from
analysis of cardiovascular prevention programmes.
Keywords Primary prevention.Cardiovascular diseases.
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Introduction
In North-West Europe, cardiovascular disease is a major
cause of death accounting for over 2 million deaths each
year (42% of all mortality causes). Cardiovascular mortality
is 55% in female and 43% in male subjects in Europe [1].
In daily care concerning cardiovascular prevention, a point
of sincere concern, is the persistent manifestation of clinical
inertia (knowing the presence of a risk factor but not acting
appropriately with an intervention). The EuroAspire initia-
tive evidently showed that patients with various established
cardiovascular risk factors are still insufficiently treated and
that this suboptimal treatment continues to exist, despite the
existence of global clinical guidelines [2]. Comparing
EuroAspire I (1997) with EuroAspire III (2009), the
proportion of undertreated dyslipidaemia appears to be
80% and 51%, respectively [2, 3]. Against this background,
several programmes have been started in Europe with the
aims to improve screening for cardiovascular risk factors in
at-risk populations.
Taking this knowledge into consideration, we evaluated
the current approach in two cardiovascular clinics in North-
West Europe (the Academic Medical Centre (AMC) of the
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and La Pitié-Salpêtrière in Paris, France). In the
Netherlands and in France, cardiovascular disease
accounts for 30% and 28%, respectively, of the total
mortality [4, 5], making it a prominent factor in daily
health care. In both countries cardiovascular clinics, as
part of cardiovascular prevention programmes, have been
evolving in the last decade and are supported by the
development of national and European clinical guidelines.
Differences in health care approach may be of importance
when comparing results from each region.
In this study we evaluated the content of the first
consultation of patients with primary dyslipidaemia as
part of cardiovascular prevention programmes that are




A retrospective analysis with a cross-sectional design was
used. All patients referred for a specialised cardiovascular
risk assessment to the vascular clinic of the AMC and the
Hôpital de Jour de Prevention Cardiovasculaire of the La
Pitié-Salpêtrière Hospital were eligible for our analysis.
These patients were referred by their general practitioner
and were already using lipid-lowering medication. Cases
were randomly selected from the total patient population
visiting these clinics from May 2008 to April 2009.
Patient selection
Patients with ages between 35 and 75 years, who were
treated in a primary prevention setting and were using lipid-
lowering drugs, were eligible for inclusion. Patients with
comorbidity (such as an established type 2 or type 1
diabetes mellitus or a thyroid or liver disease) were
excluded from the analysis, as these are confounders for
primary dyslipidaemia.
In the Netherlands and in France a total of 77 and 119
patients were included, respectively. From each patient
anthropometrics and direct data were collected, such as age,
gender, weight, height, blood pressure, smoking habits,
alcohol consumption and current lipid-lowering treatments.
Venous blood samples in fasting state were drawn to assess
lipid profile.
Description clinical programme’s environment
Information about the structure of each distinctive cardio-
vascular clinic was collected and observed while visiting
each specific centre. In the Amsterdam clinic, the guideline
of the Centraal BegeleidingsOrgaan (CBO, a governmental
institute for the enhancement of health care quality) on
cardiovascular risk management was used [6] and in the
Paris clinic, the HAS (Haute Autorité de Santé) recom-
mendations on dyslipidaemia were used [7].
Statistical analysis methods
The collected data were processed into an SPSS file.
Descriptive statistics and independent non-parametric tests
were used to evaluate differences between the French and
Dutch populations. A p-value below 0.05 (two-side tested)
was considered as statistically significant. SPSS software,
version 16, was used.
Results
Comparison of infrastructures in a French and a Dutch
cardiovascular clinic
The infrastructure of the cardiovascular clinics in which
patients are assessed is different. A schematic overview is
shown in Fig. 1.
The cardiovascular clinic of the La Pitié-Salpêtrière
Hospital is a specialised unit in which structured
evaluations of individual cardiovascular risk profiles
are performed. This structure was described previously
in detail [8]. In short, the one-day programme is guided
by a strict protocol that consists of distinctive stations in a
carousel-like structure. The vascular outpatient clinic in
the AMC has a structured protocol to include patients in
their cardiovascular prevention programme, which
expands over a longer time period. After they are
registered, patients are planned for a consultation appoint-
ment that will take place within one month’s time. Results
of blood analyses will be available at their arrival for the
first consultation. After evaluation of the individual
patient’s results, a therapeutic strategy will be determined.
The aims are discussed with the patient and the results will
be evaluated in a regular follow-up.
Comparison of French and Dutch guidelines
Comparing the distinctive guidelines, it appears that they
are rather uniform in both their approach of patients and
their interventions. One major difference between French
and Dutch guidelines is the calculation of patients’
individualised risk of the occurrence of an ischaemic event
in a timeframe of 10 years. The Dutch guideline imple-
ments the SCORE table [9]. With use of the 10-year
mortality risk and other individual factors (as family history,
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individual global risk profile is defined to establish an
intervention strategy. Risk estimation in France is done
according to the number of risk factors present, which will
determine its treatment targets. Another difference between
the two guidelines is the target level of LDL cholesterol.
The Dutch guideline aims to achieve LDL-cholesterol
levels lower than 2.5 mmol/l, or a decrease of at least
1 mmol/L for all patients with a 10-year risk of more than
10%. In France, however, distinctive targets regarding
LDL-cholesterol levels have been defined according to the
number of risk factors present; LDL-cholesterol levels
lower than 2.5 mmol/L are only pursued in secondary
prevention programmes.
Fig. 1 Flow diagram of clinic
protocols in France (left)
versus the Netherlands (right).
Schematic representation of the
infrastructure used in the
cardiovascular clinic in the
Netherlands (Lipid Outpatient
Clinic, Academic Medical
Centre, Amsterdam) and in
France (Hôpital de Jour de
Prevention Cardiovasculaire,
La Pitié-Salpêtrière hospital,
Paris), showing the steps each
patient is to take
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cardiovascular clinics
In the Dutch cardiovascular clinic 77 patients were
documented and in France a total of 119 patients. Patients’
characteristics are depicted in Table 1. Dutch patients
present to the cardiovascular clinic at younger ages
compared with French patients (p<0.001). In both countries
male patients tend to be referred at a younger age than
female patients. This finding was not, however, statistically
significant.
Lipid profiles are listed in Table 2. Lipid levels in Dutch
patients seem to be lower than in patients visiting the
French lipid clinic, but a significant difference was only
ascertained for LDL cholesterol. The averages of absolute
LDL-cholesterol levels were 3.1 mmol/L and 3.5 mmol/L
for patients in the Netherlands and in France respectively.
When arranging the two groups according to gender,
significantly lower levels of total cholesterol (p=0.01),
LDL cholesterol (p=0.009) and HDL cholesterol (p=0.02)
were found in Dutch male patients compared with French
male patients. Considering the female patients, a significant
difference was only found in HDL-cholesterol levels (p=
0.003), with French females having higher levels.
The lipid-lowering medication that patients used at their
first consultation was evaluated. Dutch patients use signif-
icantly more statins than French patients: 98% versus 75%
in male patients (p=0.002) and 97% versus 83% in female
patients (p=0.04) respectively. Considering the different
compounds in the statin group, Dutch patients use
significantly more rosuvastatin than French patients (p=
0.001). Furthermore, ezetimibe is used more often in Dutch
patients, with 32% versus 21% in Dutch and French male
patients, respectively, (p=0.18) and 36% versus 15% in
Dutch and French female patients, respectively, (p=0.03).
French patients tend to use more fibrates (not significant).
In Table 3 we show the number of patients that are ‘on
LDL-cholesterol target’ using either the Dutch or French
guideline. More Dutch patients are ‘on target’, according to
both the Dutch and the French guidelines. Considering
Dutch target levels, 29% of Dutch patients and 17% of
French patients are ‘on target’. According to French target
levels, 87% of Dutch patients and 80% of French patients
are ‘on target’. Regarding differences between genders,
more male patients are ‘on target’ compared with female
patients in the Dutch group, whereas in the French group
the number of patients ‘on target’ is more evenly distributed
among men and women.
Discussion
Despite recent efforts to develop general European guide-
lines, remarkable differences are found between currently
running cardiovascular prevention programmes in two
cardiovascular clinics in North-West Europe. This observa-
tion will warn for extrapolations from national analysis of
cardiovascular studies performed within the European
Union. Moreover, this fact may limit accurate comparisons
regarding the cardiovascular health status among European
countries and restrict collaborative therapeutic goals.
Incardiovascularprevention programmes several European
initiatives (such as the EuroAspire programme) have been
undertaken with the aim of establishing uniform clinical
approaches to patients and providing transparency of results
and subsequent treatments. The two cardiovascular
centres that we have compared use national guidelines
that are based on evidence derived from international
Table 1 Anthropometric characteristics (age, body mass index, systolic and diastolic blood pressure, smoking, use of alcohol and positive family
history) of the research population at their first consultation, specified for country and gender
Variable Netherlands France
All (n=77) Male (n=41) Female (n=36) All (n=119) Male (n=73) Female (n=46)
Mean (SD)
Age 52.2* (9.1) 49.4 (8.5) 55.3 (8.7) 58.3* (10.3) 56.5 (10.0) 62.5 (9.6)
BMI 26.8 (3.5) 27.0 (2.9) 26.7 (4.1) 26.1 (3.7) 26.1 (3.1) 26.0 (4.6)
SBP (mmHg) 129.6* (15.0) 120.0 (14.7) 129.1 (15.5) 125.0* (15.0) 125.4 (13.5) 124.3 (17.2)
DBP (mmHg) 79.7† (8.6) 80.1 (8.2) 79.2 (9.1) 71.0† (8.8) 73.7 (8.3) 66.5 (7.6)
Number (%)
Smokers 16 (20.8) 11 (26.8) 5 (13.9) 22 (18.5) 18 (24.7) 4 (8.7)
Alcohol 26 (33.8) 13 (31.7) 13 (36.1) 37 (31.1) 29 (39.7) 9 (19.6)
Positive family 48 (62.3) 25 (61.0) 23 (63.9) 61 (51.3) 38 (52.1) 23 (50.0)
BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; alcohol ≥1 unit/day; positive family is familiar
hypercholesterolaemia or cardiovascular event age <55 in first-degree male relatives, age <65 in first-degree female relatives
*p<0.05, †p<0.01
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of uniformity in treatment and clinical results regarding
cardiovascular risk factors would be present.
In this report we have shown that notable differences
nevertheless do exist in clinical approaches and subse-
quently in the number of patients ‘on target’. We observed
two marked differences between the nationally used guide-
lines: firstly in methods of cardiovascular risk assessment
and secondly the target level of LDL cholesterol. The less
rigid strategy of the French guideline towards LDL-
cholesterol target levels results in more patients being
considered ‘on target’ at their first presentation, compared
with patients assessed according to the Dutch guideline. We
also observed that the differences in target levels of LDL
cholesterol lead to a different clinical approach regarding
lipid-lowering strategies. Indeed, lipid profiles differ in the
two patient groups at their first visit. These results are in
accordance with prior literature: different assessments of
cardiovascular risk factors will result in different risk
classifications (patients in a low- or a high-risk group)
and subsequently a different treatment strategy [10].
Following these observations, we found that a difference
in the proportion of patients that achieved their treatment
targets was present when applying either the Dutch or the
French guideline. The proportion of patients ‘on target’ at
their first visit is significantly different when patients are
scored with the French guideline or the Dutch guideline.
Taking this into consideration, different reports on
achieving treatment targets regarding cardiovascular
prevention would be the outcome depending on which
guideline is used. When comparing EuroAspire I and II
with EuroAspire III [2, 3, 11], the number of patients ‘on
target’ (according to guidelines developed by Joint
European Societies) remains 50% despite more awareness
of cardiovascular prevention and increased use of statins
during the observation period. In these evaluations, the
number of patients ‘on target’ ranges from 30% to 75%
between distinctive European countries. From our results
we did indeed find the same range in the number of
patients ‘on treatment target’ according to each national
guideline (29% versus 87% in Dutch versus French guide-
lines, respectively). Our observations strongly support that,
despite the presence of evidence-based European guidelines
(ESC guidelines [12]), considerable differences still exist in
cardiovascular risk management between two European
referral centres. This finding may limit interpretation of
other European multicentre studies in which local guidelines
are applied for distinctive subpopulations. It is of importance
to notice that marked differences exist in treatment strategies
and patient profiles at their first consultation.
In conclusion, when evaluating programmes for primary
prevention of cardiovascular disease in two cardiovascular
clinics in North-West Europe, differences in currently used
guidelines are present and this could lead to a different
Table 2 Levels of serum lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides) of the patients at their first consultation,
specified for country and gender
Variable Netherlands France
All (n=77) Male (n=41) Female (n=36) All (n=119) Male (n=73) Female (n=46)
Mean (SD)
Total cholesterol (mmol/L) 5.2 (1.2) 4.9* (1.1) 5.5 (1.9) 5.5 (1.4) 5.3* (1.2) 5.8 (1.7)
LDL cholesterol (mmol/L) 3.1* (1.0) 2.9† (0.9) 3.4 (1.1) 3.5* (1.6) 3.5† (1.1) 3.6 (1.2)
HDL cholesterol (mmol/L) 1.4 (0.4) 1.2* (0.3) 1.5† (0.4) 1.3 (0.6) 1.4* (0.6) 1.2† (0.5)
Triglycerides (mmol/L) 1.7 (1.5) 1.8 (1.4) 1.5 (1.5) 1.5 (1.0) 1.5 (0.6) 1.5 (1.1)
LDL low density lipoprotein; HDL high density lipoprotein
*p<0.05, †p<0.01
Table 3 Proportion of patients that are ‘on target’, when using either the Dutch or the French guideline, assessed on both research populations
Variable Netherlands France
All (n=77) Male (n=41) Female (n=36) All (n=119) Male (n=73) Female (n=46)
Number (%)
Dutch guideline on target 22 (29) 14 (34) 9 (25) 20 (17) 12 (16) 9 (20)
French guideline on target 67 (87) 37 (90) 30 (83) 95 (80) 59 (81) 36 (78)
Dutch guideline LDL target <2.5 mmol/L; French guideline LDL target according to number of risk factors
462 Neth Heart J (2011) 19:458–463approach in health care. Despite these differences it is not
known whether this will result in a less beneficial outcome
during follow-up. Uniformity is becoming an important issue
in current daily health care. Our observations show that,
despite progress in developing European guidelines (such as
the ESC guidelines), more European initiatives that will also
highlight gender-related differences should be launched.
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